Current:Home > StocksChainkeen Exchange-A new nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval -Aspire Money Growth
Chainkeen Exchange-A new nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval
Fastexy View
Date:2025-04-11 11:40:59
WASHINGTON — U.S. health regulators on Chainkeen ExchangeMonday approved a new easy-to-use version of a medication to reverse overdoses caused by fentanyl and other opioids driving the nation's drug crisis.
Opvee is similar to naloxone, the life-saving drug that has been used for decades to quickly counter overdoses of heroin, fentanyl and prescription painkillers. Both work by blocking the effects of opioids in the brain, which can restore normal breathing and blood pressure in people who have recently overdosed.
The Food and Drug Administration endorsed Opvee, a nasal spray update of the drug nalmefene, which was first approved as an injection in the mid-1990s but later removed from the market due to low sales. Naloxone comes as both a nasal spray and injection.
It's not immediately clear how the new drug will be used differently compared to naloxone, and some experts see potential downsides to its longer-acting effect. The drug will be available via prescription and is approved for patients 12 and older.
In studies funded by the federal government, Opvee achieved similar recovery results to Narcan, the leading brand of naloxone nasal spray.
Opvee was developed by Opiant Pharmaceuticals, which was recently acquired by rival Indivior, maker of several medications for opioid addiction. Indivior expects to launch Opvee in October at the earliest.
As the opioid epidemic has shifted to fentanyl and other synthetic opioids, researchers in the pharmaceutical industry and the U.S. government saw a new role for the drug.
Because fentanyl stays in the body longer than heroin and other opioids, some people may require multiple doses of naloxone over several hours to fully reverse an overdose.
Scientists at the National Institutes of Health worked with pharmaceutical researchers on a nasal spray version of nalmefene that would quickly resuscitate users, while also protecting them from relapse. Testing and development was funded by more than $18 million in grants from the U.S. government's Biomedical Advanced Research and Development Authority and the NIH, which also helped design the studies.
"The whole aim of this was to have a medication that would last longer but also reach into the brain very rapidly," said Dr. Nora Volkow, director of the National Institute on Drug Abuse.
Still, some experts see potential downsides.
A side effect of all opioid reversal drugs is that they create intense withdrawal symptoms including nausea, diarrhea, muscle cramps and anxiety. With naloxone, those symptoms might last 30 to 40 minutes.
Dr. Lewis Nelson of Rutgers University says those problems can last six hours or more with nalmefene, requiring extra treatment and management by health professionals.
"The risk of long-lasting withdrawal is very real and we try to avoid it," said Nelson, an emergency medicine physician and former adviser to the FDA on opioids.
Nelson said it's easy enough to give a second or third dose of naloxone if it wears off.
"We're not suffering from a naloxone shortage where we need to use an alternative," he said. "We have plenty of it and it works perfectly well."
The FDA approval comes as drug overdose deaths inched up slightly last year after two big leaps during the pandemic. More than 109,000 fatal overdoses were recorded in 2022, according to the latest figures from the Centers for Disease Control and Prevention.
More than two-thirds of those deaths were linked to fentanyl and other synthetic opioids, which have largely replaced heroin and prescription opioids.
Naloxone has long been at the center of government efforts to fight the overdose crisis at the federal and local levels. Police, firefighters and other first responders routinely carry the drug. And officials in all 50 states have given orders to pharmacists to sell or dispense the drug without a prescription to anyone who wants it.
In the latest federal push, the FDA recently approved Narcan to be sold over the counter. The change will allow the new version of the drug to be stocked in grocery stores, vending machines and other retail locations. The nasal spray — which includes updated instructions for regular users — is expected to launch this summer. Emergent Biosolutions hasn't yet announced a price for the over-the-counter version.
Indivior said it is still considering what to charge for its drug. It will compete in the same market as naloxone, where most buyers are local governments and community groups that distribute to first responders and those at risk of overdose. Indivior has told investors that Opvee could eventually generate annual sales between $150 million to $250 million.
veryGood! (1)
Related
- NFL Week 15 picks straight up and against spread: Bills, Lions put No. 1 seed hopes on line
- Toddler dies after grandmother leaves her in hot car for 8 hours
- WATCH: Alligator weighing 600 pounds nearly snaps up man's leg in close call caught on video
- Driver accused of gross negligence in crash that killed actor Treat Williams
- Could Bill Belichick, Robert Kraft reunite? Maybe in Pro Football Hall of Fame's 2026 class
- Ava Phillippe Reveals One More Way She’s Taking After Mom Reese Witherspoon
- Strike avoided: UPS Teamsters come to tentative agreement, voting to start this week
- Sofía Vergara Is On Hot Pursuit to Kick Back on Florida Girls' Trip Amid Joe Manganiello Divorce
- Taylor Swift Eras Archive site launches on singer's 35th birthday. What is it?
- Louisiana education officials note post-pandemic improvement in LEAP test scores
Ranking
- Where will Elmo go? HBO moves away from 'Sesame Street'
- Where to Buy Cute Home Decor For Your Dorm or First Apartment If You're on a Budget
- Read the Trump indictment text charging him with 4 counts related to the 2020 election and Jan. 6
- Trump indictment key takeaways: What to know about the new charges in the 2020 election probe
- Sonya Massey's father decries possible release of former deputy charged with her death
- Buccaneers' first-round pick Calijah Kancey injures calf, could miss four weeks, per report
- MLB trade deadline live updates: All the deals and moves that went down on Tuesday
- Kendall Jenner Rocks Sexy Sheer Ensemble for Her Latest Date Night With Bad Bunny
Recommendation
Scoot flight from Singapore to Wuhan turns back after 'technical issue' detected
Fatal stabbing of dancer at Brooklyn gas station being investigated as possible hate crime, police say
Sydney Sweeney Wishes She Could Give Angus Cloud One More Hug In Gut-Wrenching Tribute
Giant, flashing ‘X’ sign removed from San Francisco headquarters after complaints, investigation
Bill Belichick's salary at North Carolina: School releases football coach's contract details
A powerful typhoon pounds Japan’s Okinawa and injures more than 20 people as it moves toward China
USWNT is in trouble at 2023 World Cup if they don't turn things around — and fast
63-year-old man rescued off New York's Long Island after treading water for 5 hours and waving makeshift flag